Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T in r/r B-ALL
NCT06481735Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Feb 2025
- Primary completion
- Feb 2027
- Modality
- CRISPR-Cas9, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T cell in acute lymphoblastic leukemia (ALL), sponsored by Chinese PLA General Hospital. Primary endpoints: Dose-Limiting Toxicity at 28 days, Recommended Phase 2 Dose at 12 months and 3 more. Started Feb 2025; status: recruiting.
02
Drugs
TCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T cell
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06481735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06481735.